MedTech Innovator runs an annual global competition and accelerator for early-stage medical device, diagnostic, and digital health startups, providing mentorship, strategic-partner access, and showcase exposure at major industry conferences. Selected companies get investor exposure as well as mentoring. The program is nonprofit and does not take equity.

Why it matters

Selection into the MedTech Innovator cohort is a meaningful signal for follow-on investors and strategic partners. No equity is taken in exchange for participation.

Common pitfalls

•Newer MedTech companies often underestimate the resources and time required for regulatory compliance, a critical component of successful market entry.
•Startups sometimes prioritize rapid development over robust quality management systems, leading to potential issues during regulatory submissions or post-market surveillance.
•Assuming that accelerator participation exempts a company from standard regulatory scrutiny is a significant misconception, regardless of the program’s prestige.
•Failing to integrate cybersecurity by design from the earliest stages can lead to costly redesigns and regulatory non-compliance, particularly with FDA’s premarket cybersecurity guidance for medical devices.
•Overlooking the importance of clinical evidence generation early in the development cycle can delay market access, as both FDA and EU MDR emphasize its necessity.

Sources

MedTech Innovator · MedTech Innovator
AAMI · AAMI
AdvaMed · AdvaMed

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.